These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 11803198)

  • 1. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
    Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
    Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
    Rösler M
    Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
    Stahl SM
    J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine in vascular dementia.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
    Greig NH; Lahiri DK; Sambamurti K
    Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
    J Clin Psychiatry; 2000 Apr; 61(4):307-15. PubMed ID: 10830158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.